Liquidia Corporation (LQDA)
| Market Cap | 3.32B |
| Revenue (ttm) | 158.32M |
| Net Income (ttm) | -68.92M |
| Shares Out | 88.11M |
| EPS (ttm) | -0.80 |
| PE Ratio | n/a |
| Forward PE | 15.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 747,419 |
| Open | 37.99 |
| Previous Close | 37.34 |
| Day's Range | 36.61 - 38.45 |
| 52-Week Range | 11.85 - 46.67 |
| Beta | 0.46 |
| Analysts | Strong Buy |
| Price Target | 41.00 (+8.9%) |
| Earnings Date | May 8, 2026 |
About LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L6... [Read more]
Financial Performance
In 2025, Liquidia's revenue was $158.32 million, an increase of 1031.18% compared to the previous year's $14.00 million. Losses were -$68.92 million, -46.28% less than in 2024.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for LQDA stock is "Strong Buy." The 12-month stock price target is $41.0, which is an increase of 8.90% from the latest price.
News
Liquidia Transcript: 25th Annual Needham Virtual Healthcare Conference
YUTREPIA has rapidly gained market share with strong patient uptake, robust financial performance, and broad prescriber adoption. Expansion of the sales force, new clinical studies, and a focus on displacing oral therapies are expected to drive growth toward a $1 billion revenue target by 2027. Legal and competitive dynamics remain important watchpoints.
Liquidia Analysts Boost Their Forecasts After Q4 Earnings
Liquidia Corp (NASDAQ: LQDA) reported mixed results for the fourth quarter on Thursday.
Liquidia Earnings Call Transcript: Q4 2025
YUTREPIA achieved rapid adoption and profitability, driving 74% sequential sales growth in Q4 2025 and expanding market share to 17%. Management projects continued momentum, robust cash flow, and targets $1 billion revenue by 2027, with ongoing clinical expansion.
Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
MORRISVILLE, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challeng...
Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026
MORRISVILLE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseas...
Liquidia Transcript: 44th Annual J.P. Morgan Healthcare Conference
Profitability was achieved in the first quarter of launch, with rapid market share gains and strong cash flow. Yutrepia and L606 are driving growth through new indications and clinical studies, with plans to double manufacturing capacity and expand globally.
Liquidia Transcript: Jefferies London Healthcare Conference 2025
YUTREPIA’s strong launch drove rapid revenue growth, high patient uptake, and early profitability, supported by clinical data showing superior tolerability and efficacy. Management is confident in their legal position and is preparing for all outcomes, while advancing pipeline programs and maintaining financial discipline.
Liquidia Transcript: UBS Global Healthcare Conference 2025
Strong early launch performance with rapid revenue growth and profitability, driven by differentiated inhaled treprostinil products and expanding access. Clinical data supports higher dosing and improved patient outcomes, while new studies and next-generation products target broader markets. Awaiting key patent litigation outcome but prepared for all scenarios.
Liquidia Earnings Call Transcript: Q3 2025
YUTREPIA's launch drove $51.7M in Q3 sales, rapid patient uptake, and positive adjusted EBITDA, with 85% referral-to-start conversion and broad payer access. Litigation risk remains, but market momentum and clinical expansion support strong future growth.
Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences
MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseas...
Liquidia Transcript: R&D Day 2025
Yutrepia and L606 are advancing inhaled treprostinil therapy with improved tolerability, higher dosing, and patient convenience, supported by strong clinical data and global phase III plans. Real-world adoption is high, especially in PH-ILD, and regulatory alignment supports future expansion.
Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025
MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, an...
Liquidia Corporation to Host R&D Day in New York City on October 28, 2025
MORRISVILLE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, to...
Liquidia Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
YUTREPIA's launch exceeded expectations with strong early uptake, driven by product differentiation and broad market coverage. Significant growth potential remains in PH-ILD and PAH, supported by robust payer access, a disciplined cost structure, and a strong cash position.
Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference
MORRISVILLE, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that members of the company's executive leadership team will be providing an update on the comp...
Liquidia Analysts Raise Their Forecasts Following Q2 Results
Liquidia Corporation LQDA reported a loss for the second quarter on Tuesday.
Why Is Liquidia Stock Trading Higher On Tuesday?
Liquidia Corporation LQDA reported on Tuesday a second-quarter loss of 49 cents, missing the consensus of a loss of 43 cents.
Liquidia Earnings Call Transcript: Q2 2025
YUTREPIA's launch exceeded expectations with rapid adoption, strong financial results, and broad prescriber engagement. Expanded payer contracts, robust clinical data, and a solid cash position set the stage for continued growth and manufacturing expansion.
Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update
MORRISVILLE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, t...
Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™
MORRISVILLE, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, to...
Liquidia Transcript: Jefferies Global Healthcare Conference 2025
YUTREPIA launched for PAH and PH-ILD with rapid patient access, parity pricing, and robust supply. Differentiated by PRINT technology, it targets significant market share and profitability within a year, while expanding its pipeline and defending its IP position.
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
MORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, to...
These Analysts Boost Their Forecasts On Liquidia
On Friday, the U.S. Food and Drug Administration (FDA) approved Liquidia Corporation's LQDA Yutrepia (treprostinil) inhalation powder, a prostacyclin analog for adults with pulmonary arterial hyperten...
Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference
MORRISVILLE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the company's Chief Executive Officer Dr. Roger Jeffs, Chief Financial Officer and Chief Op...
Liquidia Transcript: Status Update
YUTREPIA has received FDA approval for PAH and PH-ILD, offering differentiated dosing flexibility and a user-friendly inhaler. The commercial launch is imminent, with robust patient support and a pricing strategy at parity with competitors. Profitability is targeted within three to four quarters.